Rucaparib
- Generic Name
- Rucaparib
- Brand Names
- Rubraca
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18FN3O
- CAS Number
- 283173-50-2
- Unique Ingredient Identifier
- 8237F3U7EH
- Background
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that la...
- Indication
Rucaparib is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
...
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Associated Therapies
- Maintenance therapy
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
- Conditions
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 49
- Registration Number
- NCT03476798
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
- Conditions
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2021-08-27
- Target Recruit Count
- 290
- Registration Number
- NCT03462212
- Locations
- 🇮🇹
Ospedale Mater Salutis, Legnago, Italy
🇮🇹Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy
🇮🇹Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 18
- Registration Number
- NCT03442556
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-10-16
- Target Recruit Count
- 12
- Registration Number
- NCT03413995
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 97
- Registration Number
- NCT03397394
- Locations
- 🇺🇸
University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Northwestern University, Chicago, Chicago, Illinois, United States
🇺🇸Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 292
- Registration Number
- NCT03338790
- Locations
- 🇺🇸
Local Institution - 0037, Miami, Florida, United States
🇺🇸Local Institution - 0009, Marietta, Georgia, United States
🇺🇸Local Institution - 0012, Detroit, Michigan, United States
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
- Conditions
- Metastatic Biliary Tract CarcinomaMetastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v6 and v7Stage IVB Colorectal Cancer AJCC v7Metastatic Gastroesophageal Junction AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Metastatic Colorectal CarcinomaMetastatic Malignant Digestive System Neoplasm
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 18
- Registration Number
- NCT03337087
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
- Conditions
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Pamela Munster
- Target Recruit Count
- 22
- Registration Number
- NCT03318445
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 46
- Registration Number
- NCT03140670
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03101280
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸La Paz University Hospital, Madrid, Spain
🇫🇷Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale, Pierre Benite, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.